Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Relevance

Click to order products descending

Display 30 Products per page

Flublok
Read More
Flublok (Sanofi) is a quadrivalent recombinant seasonal influenza vaccine that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
Fluzone High-Dose
Read More
Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
Flucelvax QIV
Read More
Flucelvax is an inactivated subunit cell-based QIV that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
FluMist QIV
Read More
FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
Fluad QIV
Read More
Fluad QIV (CSL) is a subunit, surface antigen-containing seasonal quadrivalent influenza vaccine adjuvanted with MF-59, an oil-in-water emulsion. It contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
GSK-3
Read More
GSK-3 is a 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine, which also includes the conserved, unconjugated pneumococcal proteins dPly and PhtD.
December 21, 2018
Find out more
V114
Read More
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
December 21, 2018
Find out more
Prevnar 13
Read More
Prevnar 13 is Pfizer’s follow-on vaccine to Prevnar 7, which was the first pneumococcal conjugate vaccine licensed in the US.
December 21, 2018
Find out more
Synflorix
Read More
Synflorix (GlaxoSmithKline/Japan Vaccine) is a 10-valent pneumococcal conjugate vaccine active against Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
December 21, 2018
Find out more
Pneumovax 23
Read More
Pneumovax 23 is a 23-valent polysaccharide vaccine containing 23 purified capsular antigens of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.
December 21, 2018
Find out more
PF-06482077
Read More
Pfizer’s PF-06482077 is a 20-valent pneumococcal conjugate vaccine, which is currently in Phase II development in the US and EU. PF-06482077 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as seven additional serotypes.
December 21, 2018
Find out more
Evinacumab
Read More
Evinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein lipase and endothelial lipase.
November 20, 2018
Find out more
Epanova
Read More
Epanova (omefas; AstraZeneca) is an omega-3 fatty acid drug developed for the treatment of severe hypertriglyceridemia. It contains a novel free fatty acid formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
November 20, 2018
Find out more
ralinepag
Read More
Ralinepag (Arena Pharmaceuticals/Everest Medicines) is a selective prostaglandin I2 receptor agonist. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, which also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more
esuberaprost
Read More
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more
bardoxolone methyl
Read More
Bardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary arterial hypertension.
October 29, 2018
Find out more
INOpulse
Read More
INOpulse (Bellerophon Therapeutics) is a drug-device combination being developed to deliver a continuous, pulsed dose of nitric oxide via intranasal inhalation.
October 29, 2018
Find out more
Aurora-GT
Read More
United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)
October 29, 2018
Find out more
Tyvaso
Read More
United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil
October 29, 2018
Find out more
Revatio
Read More
Revatio (sildenafil), manufactured by Pfizer, is a selective inhibitor of the phosphodiesterase 5 (PDE5) enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more
Remodulin
Read More
Remodulin (treprostinil; United Therapeutics/Antigen/Mochida) is a prostaglandin analog that functions as a prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
Opsumit
Read More
Actelion’s Opsumit (macitentan) is the follow-on product to the leading pulmonary arterial hypertension (PAH) therapy Tracleer.
October 29, 2018
Find out more
Adempas
Read More
Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells.
October 29, 2018
Find out more
Letairis
Read More
Letairis (ambrisentan; Gilead/AbbVie/GlaxoSmithKline) is a selective endothelin type A (ETA) receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory.
October 29, 2018
Find out more
Uptravi
Read More
Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
Tracleer
Read More
Actelion’s Tracleer (bosentan) was the first oral therapy to be developed specifically for the treatment of pulmonary arterial hypertension (PAH).
October 29, 2018
Find out more
Adcirca
Read More
Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more
Orenitram
Read More
United Therapeutics’ Orenitram (trepostinil) is the first-to-market oral formulation of a prostacyclin analog, and is a reformulation of the company’s intravenous prostacyclin analog Remodulin.
October 19, 2018
Find out more
Blincyto
Read More
Blincyto, produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant B-cells. It activates endogenous T-cells by connecting…
October 9, 2018
Find out more
Selinexor
Read More
Selinexor (Karyopharm/NPM Pharma) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1.
October 9, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *